Skip to main content

Pliant Therapeutics, Inc.

corporate_fare Company Profile

Pliant Therapeutics, Inc.

PLRX·NASDAQ·Life Sciences·CIK 0001746473

The company is a clinical-stage biopharmaceutical company that discovers and develops integrin-based treatments. Its primary focus is on developing therapies for solid tumors by blocking integrin-mediated activation of transforming growth factor-β (TGF-β). The company uses its knowledge of integrin biology, medicinal chemistry, and translational medicine to operate a proprietary drug discovery platform. Its wholly owned lead product candidate, PLN-101095, is an oral, small molecule that selectively inhibits both αvβ8 and αvβ1 integrins. This candidate is being developed to treat solid tumors. In 2025, the company reported positive data from a Phase 1 open-label dose-escalation trial of PLN-101095. This trial evaluated PLN-101095 as a standalone treatment and in combination with the immunotherapy pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. The company is also exploring its drug discovery platform, which includes a proprietary library of over 15,000 integrin binding molecules, with a focus on integrin-based target-mediated drug delivery. PLN-101095 targets the TGF-β activating integrins αvβ8 and αvβ1, which are elevated in certain tumors, aiming to make tumors more responsive to checkpoint inhibitors. In March 2025 and December 2025, the company announced positive data from a Phase 1 open label dose-escalation trial of PLN-101095.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for PLRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for PLRX spans 10-Q, 8-K, DEF 14A, S-3.

Recent high-impact activity:

  • Pliant Q3 Loss Narrows to $24.4M; Discloses Nasdaq $1.00 Bid-Price Deficiency
  • Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028; FORTIFY Trial Enrollment Ahead of Schedule
  • Pliant Therapeutics Reports Strong Q2: Narrows Loss, Extends Cash Runway, Advances Oncology Program
  • Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028 as Oncology Pipeline Advances
  • Q1 Net Loss Narrows Significantly, Cash Burn Halves Amid Strategic Refocus

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$149.34M
Diluted EPS
-$2.43
Op. Cash Flow
-$128.34M
Free Cash Flow
-$128.71M
Operating Income
-$156.37M
Cash & Equivalents
$45.45M
Total Debt
$0
Debt / Equity
0.00×
Shares Outstanding
61.45M sh
Source: 10-K · filed 2026-03-11 · accession 0001746473-26-000037

Short Interest & Short Volume

16.20 days to cover

FINRA reported short interest of 4,881,070 shares in PLRX as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 16.2 days to cover at its recent average daily volume. On November 19, 2026, 30.5% of PLRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,881,070 shares as of October 30, 2026
Change vs prior period▲ 5.3%
Days to cover16.20 at avg daily volume of 301,369
Daily short volume (FINRA facilities)30.5% of 375,216 shares on November 19, 2026
5-day average short volume30.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$0.5913 -4.63% today
52-week range · as of 2026-11-12 $0.5913 – $1.81
Market cap
$36.57M
Volume
906.2K (2.0× avg)
3-mo avg 445.6K
Live data · 2026-11-20 20:57 UTC · Market open

show_chartPrice Chart

Loading chart...

feed PLRX - Latest Insights

PLRX
Nov 12, 2026, 4:09 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.780
Real-time Price: $0.5913 info
Change: -$0.1887 (-24%) info
Market Cap: $36.574M info
PLRX
Aug 11, 2026, 4:19 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.5913 info
Change: -$0.4787 (-45%) info
Market Cap: $36.574M info
PLRX
Aug 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.5913 info
Change: -$0.4787 (-45%) info
Market Cap: $36.574M info
PLRX
Aug 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.5913 info
Change: -$0.4587 (-44%) info
Market Cap: $36.574M info
PLRX
May 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.5913 info
Change: -$0.6348 (-52%) info
Market Cap: $36.574M info
PLRX
May 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.5913 info
Change: -$0.6387 (-52%) info
Market Cap: $36.574M info
PLRX
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.5913 info
Change: -$0.6348 (-52%) info
Market Cap: $36.574M info
PLRX
Apr 22, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.29
Real-time Price: $0.5913 info
Change: -$0.6987 (-54%) info
Market Cap: $36.574M info
PLRX
Apr 17, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $0.5913 info
Change: -$0.7287 (-55%) info
Market Cap: $36.574M info
PLRX
Mar 30, 2026, 5:57 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $0.5913 info
Change: -$0.5487 (-48%) info
Market Cap: $36.574M info
PLRX
Mar 30, 2026, 5:43 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $0.5913 info
Change: -$0.6287 (-52%) info
Market Cap: $36.574M info
PLRX
Mar 11, 2026, 4:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.32
Real-time Price: $0.5913 info
Change: -$0.7287 (-55%) info
Market Cap: $36.574M info
PLRX
Mar 11, 2026, 4:28 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $1.30
Real-time Price: $0.5913 info
Change: -$0.7133 (-55%) info
Market Cap: $36.574M info
PLRX
Mar 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $0.5913 info
Change: -$0.7287 (-55%) info
Market Cap: $36.574M info
PLRX
Mar 03, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.5913 info
Change: -$0.6587 (-53%) info
Market Cap: $36.574M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets